This is consistent with previously reported results that cantharidin combination therapy will promote increases in CD8 + T cells and CD4 + Teff cells among tumour infiltrating lymphocytes to inhibit lung cancer growth [29]. The gene discussed is CD8A; the disease is lung carcinoma.